Novel N 2-Substituted pyrazolo[3,4- d ]pyrimidine adenosine A3 receptor antagonists: Inhibition of A3-Mediated human glioblastoma cell proliferation

Journal of Medicinal Chemistry

Volumn 53, Issue 10, 2010, Pages 3954-3963

  Taliani, Sabrina ^a   La Motta, Concettina ^a   Mugnaini, Laura ^a   Simorini, Francesca ^a   Salerno, Silvia ^a   Marini, Anna Maria ^a   Da Settimo, Federico ^a   Cosconati, Sandro ^b   Cosimelli, Barbara ^b   Greco, Giovanni ^b   Limongelli, Vittorio ^b   Marinelli, Luciana ^b   Novellino, Ettore ^b   Ciampi, Osele ^a   Daniele, Simona ^a   Trincavelli, Maria Letizia ^a   Martini, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PYRAZOLO[3,4 D]PYRIMIDINE DERIVATIVE; ADENOSINE A3 RECEPTOR; CYCLIC AMP; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CYCLIZATION; DRUG ACTIVITY; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYMATIC ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; MICROWAVE IRRADIATION; PROTEIN PHOSPHORYLATION; PROTON NUCLEAR MAGNETIC RESONANCE; ADJUVANT CHEMOTHERAPY; ANIMAL; BINDING COMPETITION; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL; CRICETULUS; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; HAMSTER; METABOLISM; PHOSPHORYLATION; RADIOASSAY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; ENZYME ACTIVATION; GLIOBLASTOMA; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MODELS, MOLECULAR; PHOSPHORYLATION; PYRAZOLES; PYRIMIDINES; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952711968     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901785w     Document Type: Article

References (54)

1. Poulsen, S.-A.; Quinn, R. J. Adenosine receptors: new opportunities for future drugs Bioorg. Med. Chem. 1998, 6, 619-641
2. Fredholm, B. B.; Arslan, G.; Halldner, L.; Kull, B.; Schulte, G.; Wasserman, W. Structure and function of adenosine receptors and their genes Naunyn-Schmiedebergs Arch. Pharmacol. 2000, 362, 364-374
3. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors Pharmacol. Rev. 2001, 53, 527-552
4. Schulte, G.; Fredholm, B. B. Signalling from adenosine receptors to mitogen-activated protein kinases Cell. Signalling 2003, 15, 813-827
5. Jacobson, K. A.; Gao, Z.-G. Adenosine receptors as therapeutic targets Nat. Rev. Drug Discovery 2006, 5, 247-264
6. Moro, S.; Gao, Z.-G.; Jacobson, K. A.; Spalluto, G. Progress in the pursuit of therapeutic adenosine receptor antagonists Med. Res. Rev. 2006, 26, 131-159
7. 3 Adenosine Receptor with Widespread Tissue Distribution Mol. Pharmacol. 1993, 44, 524-532
8. 3 receptors: pharmacological properties, species differences and receptor functions Trends Pharmacol. Sci. 1994, 15, 298-306
9. 3 receptor: sustained cardioprotection Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 6995-6999
10. 3 adenosine receptor-mediated protection of the ischemic heart Vasc. Pharmacol. 2005, 42, 271-279
11. Akkari, R.; Burbiel, J. C.; Hockemeyer, J.; Müller, C. E. Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs Curr. Top. Med. Chem. 2006, 6, 1375-1399
12. - channels of nonpigmented ciliary epithelial cells Am. J. Physiol. 1999, 276, 659-666
13. 3 adenosine receptor affects cell cycle progression and cell growth Naunyn-Schmiedebergs Arch. Pharmacol. 2000, 361, 225-234
14. 3 Adenosine Receptors in Human Tumor Cell Lines Curr. Med. Chem. 2005, 12, 1319-1329
15. 3 Adenosine Receptors in Human Colorectal Cancer is Reflected in Peripheral Blood Cells Clin. Cancer Res. 2004, 10, 5895-5901
16. 3 Receptor Subtype Curr. Top. Med. Chem. 2003, 3, 463-469
17. 3 Adenosine Subtype J. Cell. Physiol. 2007, 211, 826-836
18. Merighi, S.; Mirandola, P.; Varani, K.; Gessi, S.; Capitani, S.; Leung, E.; Baraldi, P. G.; Tabrizi, M. A.; Borea, P. A. Pyrazolotriazolopyrimidine derivatives sensitive melanoma cells to the chemiotherapic drugs: taxol and vindesine Biochem. Pharmacol. 2003, 66, 739-748
19. Morrone, F. B.; Jacques-Silva, M. C.; Horn, A. P.; Bernardi, F.; Schwartsmann, G.; Rodnight, R.; Lenz, G. Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines J. Neuro-Oncol. 2003, 64, 211-218
20. Merighi, S.; Benini, A.; Mirandola, P.; Gessi, S.; Varani, K.; Leung, E.; Maclennan, S.; Borea, P. A. Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells Biochem. Pharmacol. 2006, 72, 19-31
21. 1 adenosine receptor antagonists J. Med. Chem. 2001, 44, 316-327
22. 1 adenosine receptor antagonists J. Med. Chem. 2002, 45, 5030-5036
23. 1 Adenosine receptor antagonists, 3-aryl[1,2,4]triazinobenzimidazol-4-(10 H)-ones (ATBIs) and N -alkyl and N -acyl-(7-substituted-2-phenylimidazo[1,2- a ][1,3,5]triazin-4-yl) amines (ITAs): different recognition of bovine and human binding sites Drug Dev. Res. 2004, 63, 1-7
24. 3 Adenosine Receptors Designed by 3D Database Searching J. Med. Chem. 2005, 48, 8253-8260
25. 3 Adenosine Receptor Antagonists J. Med. Chem. 2007, 50, 5676-5684
26. 3 Adenosine Receptor Antagonists J. Med. Chem. 2008, 51, 1764-1770 (Pubitemid 351438858)
27. Da Settimo, F.; Primofiore, G.; La Motta, C.; Taliani, S.; Simorini, F.; Marini, A. M.; Mugnaini, L.; Lavecchia, A.; Novellino, E.; Tuscano, D.; Martini, C. Novel, Highly Potent Adenosine Deaminase Inhibitors Containing the Pyrazolo[3,4- d ]pyrimidine Ring System. Synthesis, Structure-Activity Relationships, and Molecola Modeling Studies J. Med. Chem. 2005, 48, 5162-5174
28. Antonioli, L.; Fornai, M.; Colucci, R.; Ghisu, N.; Da Settimo, F.; Natale, G.; Kastsiuchenka, O.; Duranti, E.; Virdis, A.; Vassalle, C.; La Motta, C.; Mugnaini, L.; Breschi, M. C.; Blandizzi, C.; Del Tacca, M. Inhibition of Adenosine Deaminase Attenuates Inflammation in Experimental Colitis J. Pharmacol. Exp. Ther. 2007, 322, 435-442
29. Chebib, M.; Quinn, R. J. Pyrazolo[3,4- d ]pyrimidines; Adenosine Receptor Selectivity Bioorg. Med. Chem. Lett. 1995, 5, 2409-2412
30. Chebib, M.; Quinn, R. J. 1-Phenylpyrazolo[3,4- d ]pyrimidines as Adenosine Antagonists: The Effects of Substituents at C4 and C6 Bioorg. Med. Chem. 1997, 5, 311-322
31. 2A antagonistic activity Pharmazie 2005, 60, 732-735
32. 3 Receptor Subtypes J. Med. Chem. 1996, 39, 4142-4148
33. 3 Adenosine Receptor Ligands: History and Perspectives Med. Res. Rev. 2000, 20, 103-128
34. Baraldi, P. G.; Cacciari, B.; Borea, P. A.; Varani, K.; Pastorin, G.; Da Ros, T.; Tabrizi, M. A.; Fruttarolo, F.; Spalluto, G. Pyrazolo-Triazolo- Pyrimidine Derivatives as Adenosine Receptor Antagonists: A Possible Template for Adenosine Receptor Subtypes? Curr. Pharm. Des. 2002, 8, 2299-2332
35. 3 Receptor Ligands. 2. Structure-Affinity Profile of a Series of Isoquinoline and Quinazoline Compounds J. Med. Chem. 1998, 41, 3994-4000
36. 3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies J. Med. Chem. 2006, 49, 3916-3925
37. Nordstedt, C.; Fredholm, B. B. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid Anal. Biochem. 1990, 189, 231-234
38. 2B receptor with an improved selectivity profile compared to the reference agonist N -ethylcarboxamidoadenosine J. Med. Chem. 2004, 47, 3707-3709
39. 1 receptor J. Med. Chem. 2005, 48, 2045-2053
40. 2A adenosine receptor bound to an antagonist Science 2008, 322, 1211-1217
41. 3 Adenosine Receptor Antagonists: New Insights into the Receptor-Antagonist Recognition J. Med. Chem. 2009, 52, 7640-7652
42. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A Semiempirical Free Energy Force Field with Charge-Based Desolvation J. Comput. Chem. 2007, 28, 1145-1152
43. 2A adenosine receptor J. Biol. Chem. 1995, 270, 13987-13997
44. 3 adenosine receptor J. Biol. Chem. 2002, 277, 19056-19063
45. The CLogP, ASA, and TPSA calculations were performed with the Marvin Sketch and Calculator Plugins on the website http://www.chemaxon.com/demosite/ marvin/index.html.
46. 3 receptor modulators for therapeutic and diagnostic use. U.S. Patent Appl. US6407236 B1 20020618, 2002.
47. Klotz, K.-N.; Hessling, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B. B.; Lohse, M. J. Comparative pharmacology of human adenosine receptor subtypes characterization of stably transfected receptors in CHO cells Naunyn-Schmiedebergs Arch. Pharmacol. 1998, 357, 1-9
48. 50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
49. 3 receptors protect astrocytes from hypoxic damage Eur. J. Pharmacol. 2008, 596, 6-13
50. Prime, version 2.0; Schrödinger, LLC, New York, 2005.
51. Maestro, version 8.5; Schrödinger, LLC, New York, 2006.
52. Jacobson, M. P.; Pincus, D. L.; Rapp, C. S.; Day, T. J.; Honig, B.; Shaw, D. E.; Friesner, R. A. A hierarchical approach to all-atom protein loop prediction Proteins 2004, 55, 351-367
53. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A Semiempirical Free Energy Force Field with Charge-Based Desolvation J. Comput. Chem. 2007, 28, 1145-1152
54. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-A Visualization System for Exploratory Research and Analysis J. Comput. Chem. 2004, 25, 1605-1612